A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex [CDB 4124; Repros Therapeutics] in the Treatment of Premenopausal Women With Symptomatic Endometriosis.
Latest Information Update: 21 Oct 2014
At a glance
- Drugs Telapristone (Primary)
- Indications Endometriosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Repros Therapeutics
- 14 Aug 2009 Planned end date changed from 1 Feb 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
- 05 Jun 2009 Actual end date changed from Feb 2009 to Jul 2009 as reported by ClinicalTrials.gov.
- 13 Jan 2009 Results reported by Repros Therapeutics.